Saturday 17 October 2026
Export LITS’s income statement to Excel — free account
Lite Strategy, Inc.
LITS Healthcare Biotechnology
Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023. In the quarter to June 2026, EPS fell 11.0% and free cash flow grew 179.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
1.14
0.06
−5.00%
Follow LITS
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 5 | 3 | 4 | 4 | 6 | 4 | — | — |
P/E ratio |
— | — | 1.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.83 |
Altman Z-Score |
— | — | (8.07) | (4.17) | (2.79) | (0.98) | 0.69 | (1.64) | (0.84) | 8.11 |
P/S ratio |
— | — | 0.18 | 0.90 | 1.87 | 9.22 | 13.55 | 36.47 | 102.43 | 3.78 |
Altman Z″-Score (non-manufacturers) |
— | — | (18.94) | (8.00) | (4.01) | (2.45) | 1.56 | (6.04) | (1.49) | 7.00 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 11.28 | 0.00 | 0.00 | 25.61 |
Beneish M-Score |
— | — | — | (2.12) | (2.40) | (3.44) | (0.84) | — | — | — |
P/Operating CF |
— | — | (1.05) | (3.88) | (4.90) | (28.49) | 5.44 | (22.23) | (47.70) | (27.97) |
P/B ratio |
— | — | 0.58 | 1.78 | 1.45 | 6.48 | 4.88 | 3.74 | 3.29 | 1.73 |
Price to Tangible BV |
— | — | 0.58 | 1.80 | 1.46 | 6.51 | 4.90 | 3.76 | 3.31 | 1.74 |
EV/Sales |
— | — | (0.18) | (1.16) | (1.90) | 4.81 | 6.97 | 21.32 | 39.09 | 1.48 |
EV/EBITDA |
— | — | 0.00 | 1.56 | 1.03 | 0.00 | 0.00 | 0.00 | 0.00 | 13.94 |
EV/Operating CF |
— | — | 0.38 | 1.08 | 1.59 | (5.23) | 5.65 | (3.56) | (3.01) | 9.87 |
EV/FCF |
— | — | 0.38 | 1.08 | 1.57 | (5.12) | 5.80 | (3.53) | (3.01) | 10.02 |
Quick Ratio |
5.34 | 13.30 | 4.59 | 4.95 | 6.68 | 7.97 | 14.97 | 5.58 | 13.03 | 11.01 |
Current Ratio |
5.74 | 13.50 | 4.88 | 5.29 | 6.84 | 8.15 | 15.17 | 5.75 | 13.23 | 11.37 |
Net Debt/EBITDA |
0.09 | 1.05 | (1.48) | 2.77 | 2.04 | 2.55 | 7.20 | 1.61 | 3.60 | (21.69) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.81 | 0.33 | 0.23 | 0.18 | 0.19 | 0.05 | 0.02 | 0.45 |
Operating CF/Net income |
0.13 | 1.31 | (2.84) | 1.65 | 0.90 | 0.77 | (0.73) | 1.75 | 0.53 | 1.31 |
Capex/Depreciation |
0.00 | 0.03 | 0.00 | (0.09) | (1.47) | (2.48) | (2.66) | (2.71) | 0.00 | (0.60) |
| (243.02%) | (63.84%) | 61.68% | (82.66%) | (106.90%) | (65.30%) | (75.48%) | (34.19%) | (79.11%) | 5.77% | |
| (233.37%) | (53.45%) | 21.92% | (21.32%) | (30.95%) | (21.53%) | (32.27%) | (17.96%) | (49.97%) | 5.19% | |
ROIC |
(115.85%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(1,402.80%) | (94.18%) | 54.19% | (35.98%) | (37.73%) | (28.28%) | (24.07%) | (24.70%) | (41.53%) | 5.29% |
Average Days of Receivables |
— | — | 0.00 | 0.64 | 90.08 | 79.53 | 306.11 | 391.66 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 25.36% | 107.44% | 210.44% | 199.44% | 122.73% | 657.17% | 1,050.43% | 31.13% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 35.68% | 67.87% | 75.04% | 70.16% | 60.23% | 296.99% | 603.39% | 37.11% |
Intangible Assets out of Total Assets |
0.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 3.49% | 7.35% | 20.52% | 29.44% | 24.50% | 133.51% | 198.34% | 9.91% |
Graham Net Nets |
— | — | 1.71 | 0.26 | 0.55 | 0.13 | 0.20 | 0.26 | 0.30 | 0.57 |
Graham Number |
— | — | 17.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.31 |
Earnings Yield |
— | — | 93.68% | (70.36%) | (72.35%) | (14.72%) | (12.35%) | (9.52%) | (22.94%) | 2.51% |
Free Cash Flow Yield |
— | — | (266.05%) | (119.79%) | (64.83%) | (10.19%) | 8.87% | (16.56%) | (12.69%) | 3.90% |
Revenue per Share |
0.00 | 0.00 | 9.80 | 7.33 | 6.54 | 6.18 | 6.09 | 1.38 | 0.78 | 12.63 |
Operating CF per Share |
(0.26) | (3.13) | (7.58) | (7.88) | (7.83) | (5.68) | 7.52 | (8.27) | (10.15) | 1.89 |
Capex per Share |
(2.75) | 0.00 | 0.00 | (0.01) | (0.08) | (0.13) | (0.20) | (0.06) | 0.00 | (0.03) |
Free Cash Flow per Share |
(3.01) | (3.13) | (7.58) | (7.88) | (7.91) | (5.81) | 7.33 | (8.33) | (10.15) | 1.87 |
Cash per Share |
0.17 | 2.70 | 5.75 | 15.11 | 24.62 | 27.27 | 40.10 | 20.94 | 49.60 | 29.10 |
Shareholders Equity per Share |
1.20 | 2.54 | 4.96 | 3.70 | 8.42 | 8.79 | 16.92 | 13.47 | 24.36 | 27.62 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.20 | 2.54 | 4.96 | 3.70 | 8.42 | 8.79 | 16.92 | 13.47 | 24.36 | 27.62 |
Free Cash Flow |
(104.08) | (20.83) | (50.48) | (52.52) | (49.22) | (32.67) | 33.36 | (29.64) | (21.03) | 3.44 |
Working Capital |
5.07 | 16.93 | 32.41 | 87.19 | 142.68 | 144.61 | 194.89 | 67.90 | 96.44 | 50.46 |
Capital Expenditures |
(94.96) | 0.01 | (0.01) | (0.03) | (0.48) | (0.71) | (0.89) | (0.22) | — | (0.05) |
Net Current Asset Value |
5.07 | 16.93 | 32.41 | 11.34 | 41.70 | 40.19 | 75.98 | 47.47 | 50.13 | 50.46 |
EV/EBIT |
— | — | 0.00 | 1.55 | 1.02 | 0.00 | 0.00 | 0.00 | 0.00 | 14.44 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.03 | 0.04 | 0.00 | 0.00 |
Price to Operating Income |
— | — | 1.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.91 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | 0.00 | 28.78 | 0.29 | 0.20 | 0.19 | 0.31 | 0.39 | 1.66 | 1.70 |
Cash ROIC |
(219.91%) | (59.62%) | (70.73%) | (41.91%) | (23.93%) | (16.10%) | 12.85% | (24.21%) | (13.73%) | 3.29% |
Accounts Receivable Turnover |
— | — | 0.00 | 9.64 | 4.62 | 2.26 | 1.94 | 0.33 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.32 | 0.74 | 1.01 | 1.60 | 6.01 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,647.43 | 333.02 | 409.87 | 393.05 | 42.71 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 5.06 | 8.81 | 15.43 | 14.28 | 14.79 | — | — |
Average Payables |
0.22 | 1.67 | 4.65 | 7.03 | 7.14 | 4.40 | 3.61 | 4.22 | 2.11 | 0.83 |
Average Assets |
30.49 | 29.83 | 81.09 | 149.32 | 175.97 | 191.91 | 146.20 | 93.66 | 80.18 | 51.43 |
Average Common Equity |
29.28 | 24.98 | 28.82 | 38.52 | 50.94 | 63.26 | 62.50 | 49.19 | 50.65 | 46.25 |
Columns are period end dates · fundamentals updated 30 Sep 2026